Software Engineer

Mike Gelber, Chief Product Officer at Impiricus, named to MM+M's 40 Under 40 list. NEW YORK, NY - December 4, 2025 - MM+M has announced its seventh class of 40 Under 40 honorees, recognizing Mike Gelber, Chief Product Officer at Impiricus, the #1 fastest growing company in North America according to Deloitte. Gelber is honored for pioneering the future of ethical physician-pharma collaboration through the launch of Impiricus Ascend, an AI-powered communication platform that is fundamentally changing how healthcare professionals (HCPs) access critical resources. The MM+M 40 Under 40 list celebrates young leaders whose strategic thinking and digital facility contribute significantly to the healthcare industry's growth. "The individuals on the list are laying the foundation upon which the future of this industry will be built. They are creating a more equitable, inclusive landscape that will help pharma and biotech companies reach all patient populations," said MM+M editor-in-chief Jameson Fleming. Mike Gelber is the product visionary behind Ascend, Impiricus' flagship platform that resolves the physician pain point of information overload and accelerates patient access to care. Ascend is the solution for meeting HCPs where they are, cutting through the noise with personalized, efficient, and ethical pharma resource delivery. The platform is powered by proprietary AI models trained on over four billion HCP data points. Ascend leverages a unique, agentic AI delivery system with secure, tokenized data pipelines to amplify access to pharma resources for underserved physicians. This secure mobile-first experience allows physicians to connect with a representative in real-time and access essential resources like samples, treatment information, and dosing calculators. "Mike Gelber's dedication to AI innovation for ethical, HCP engagement is transforming how the pharma industry supports providers. Physicians report that these connections are helping patients access critical medications faster without the time burden of the traditional pharma model," said Dr. Osama Hashmi, Dermatologist, CEO and Co-founder of Impiricus. Impiricus has now been named the #1 fastest growing company in North America by the Deloitte Fast 500. Impiricus is the first and only AI-powered HCP Engagement Engine. Founded by a practicing physician and a senior pharmaceutical executive, Impiricus was created to transform how life sciences companies support physicians. Impiricus, Inc. ethically connect HCPs to pharma resources, reduce go-to-market costs and accelerate patient access to the treatments they need. With its unique access to the largest opted-in network of HCPs, their insights, and clinical expertise, Impiricus, Inc. is the leading provider of AI technology and real-time channels that life science companies need to deliver clear, reliable, and evidence-based resources directly into the hands of HCPs. Guided by a council of 2000+ trusted HCP advisors, Impiricus, Inc. ensure every interaction is clinically meaningful, ethically grounded and leads to better patient care. Read its content. News and insights. Mike Gelber, Chief Product Officer at Impiricus, named to MM+M's 40 Under... NEW YORK, NY - December 4, 2025 - MM+M has announced its... Deloitte unveils 2025 North America technology Fast 500(TM) rankings. NEW YORK, Nov. 19, 2025 /PRNewswire/ - Deloitte today released its "North... Impiricus launches Ascend, an AI platform to ethically connect physicians and pharma. Today's healthcare environment is marked by rapid drug advancements, evolving patient expectations,...

Impiricus launches ascend, an AI platform to ethically connect physicians and pharma. News provided by. Ascend sets a new standard in physician support through precision-tailored new resources to give patients faster, more reliable access to the treatments they need. ATLANTA, Nov. 13, 2025 /PRNewswire/ - Impiricus, a platform that connects healthcare providers with pharmaceutical and life sciences companies for equitable access to resources and improved patient care, today announced the launch of Impiricus Ascend, an AI-powered communication platform that ethically connects physicians to pharma resources. Physicians today face an overload of pharmaceutical outreach and information across multiple channels, creating a need to meet HCPs where they are for a more efficient, personalized solution. With Ascend, physicians are able to cut through the noise and act immediately on tailored, patient-focused resources that are aligned with their preferences and schedules. This approach ensures a new level of clinical support, reduced go-to-market costs and accelerated patient access to the needed treatments. Built on Impiricus' proprietary AI models trained on over four billion healthcare professional (HCP) data points and interactions, Ascend leverages a unique, agentic AI delivery platform that extends beyond the capabilities of basic chatbots. Ascend pairs fine-tuned AI agents with secure, tokenized data pipelines, where sensitive information is broken into anonymized, non-identifiable units, to amplify access to pharma resources for underserved physicians. This allows physicians to connect with a representative in real-time and access pharma resources such as samples, treatment information, order assistance, dosing calculators, and patient resources. Top pharmaceutical companies are using Ascend to amplify their field forces and provide a layer of regulated interactions with underserved HCPs. This enables faster reach for new therapies, sustained brand support, and greater engagement with previously unresponsive physicians. Ascend amplifies commercial and medical teams while keeping patient impact at the center of every interaction. "Since founding Impiricus, our mission has been to build ethical connections between pharma and physicians that ultimately help patients. Ascend gives doctors choice and relevance in how they engage, while giving pharma a responsible way to share information. The result is clearer communication, better decision-making, and more patients getting the treatments they need." said Dr. Osama Hashmi, Dermatologist, CEO and Co-founder of Impiricus Ascend has already shown strong early results across the industry. A top five pharmaceutical company used the platform to reach digitally naïve physicians for a mature brand, driving a $60 million lift in just a few months. A newly launched biotech with no field force was able to engage thousands of top-tier providers without any physical presence. Most importantly, physicians report that these connections are helping patients access critical medications faster without the time burden of the traditional pharma model. Impiricus Ascend is now available to existing and new life science partners. To learn more, send a message to [email protected]. About Impiricus Impiricus is the first and only AI-powered HCP Engagement Engine. Founded by a practicing physician and a senior pharmaceutical executive, Impiricus was created to transform how life sciences companies support physicians. We ethically connect HCPs to pharma resources, reduce go-to-market costs and accelerate patient access to the treatments they need. With our unique access to the largest opted-in network of HCPs, their insights, and clinical expertise, we are the leading provider of AI technology and real-time channels that life science companies need to deliver clear, reliable, and evidence-based resources directly into the hands of HCPs. Guided by a council of 2000+ trusted HCP advisors, we ensure every interaction is clinically meaningful, ethically grounded and leads to better patient care. Partner with us: https://impiricus.com/contact-us/ SOURCE Impiricus